I considered Nerlynx as an immunotherapy after completing chemo (Taxotere, Carboplain) and targeted therapy (Herceptin), for Stage 2 HER2+. Because I was not elegible for retirement from the school system yet, I passed on Nerlynx. It would have provided only minimal risk reduction (at best 2%) and with a side effect of "chronic diarrhea", I just did not feel it was a good match at that time. I told the oncologist that would be something I would consider should the HER2+ return. I consider it a spare arrow in the quiver, Keeping you in prayers as you and your team find something that will suit you and your circumstances. Please keep me posted- this HER2+ gal is rooting for you! Hugs!
July 22
Great question! For stage 4 (metastatic) breast cancer, there are several oral/pill-based treatment options depending on the type of breast cancer. Here's a quick overview:
HER2-Positive Breast Cancer
- Neratinib (Nerlynx) β an oral pill often prescribed for those who have previously been treated with trastuzumab-based Show Full Answer
Great question! For stage 4 (metastatic) breast cancer, there are several oral/pill-based treatment options depending on the type of breast cancer. Here's a quick overview:
HER2-Positive Breast Cancer:
- Neratinib (Nerlynx) β an oral pill often prescribed for those who have previously been treated with trastuzumab-based therapy
Hormone Receptor-Positive (HR+) Breast Cancer:
- Tamoxifen β targets hormone receptors
- Exemestane (Aromasin) β another hormone therapy option
- Palbociclib (Ibrance) β a kinase inhibitor for HER2-negative, ER-positive cancers
- Abemaciclib (Verzenio) β another option in this category
HER2-Negative Breast Cancer:
- Olaparib (Lynparza) β a PARP inhibitor that may be used following chemotherapy It's really important to note that the best oral treatment depends on your cancer's specific features β like HER2 status, hormone receptor status, and genetic traits. Each person's treatment plan needs to be tailored specifically to them.
Always discuss these options with your oncologist to find what's right for your situation. They'll weigh the benefits against potential risks for each medication.
July 22